Stockreport

Zafgen updates on obesity drug [Seeking Alpha]

ZAFGEN INC  (ZFGN) 
Last zafgen inc earnings: 3/5 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: zafgen.gcs-web.com/investor-relations
PDF Zafgen (NASDAQ: ZFGN ) says  MetAP2 inhibitor ZGN-1061 was well tolerated and safe in a Phase 1 trial on obesity. The trial indicated improvements in metabolic [Read more]